Equitable Trust Co. Sells 1,580 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Equitable Trust Co. cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 12,885 shares of the medical equipment provider’s stock after selling 1,580 shares during the period. Equitable Trust Co.’s holdings in Lantheus were worth $1,153,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the 3rd quarter worth approximately $25,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. boosted its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares during the period. Kathleen S. Wright Associates Inc. bought a new position in Lantheus in the 3rd quarter worth approximately $51,000. Finally, GAMMA Investing LLC boosted its holdings in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the period. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on LNTH shares. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $86.91 on Tuesday. The firm’s fifty day moving average price is $92.02 and its 200-day moving average price is $98.46. The stock has a market cap of $6.04 billion, a P/E ratio of 14.46 and a beta of 0.44. Lantheus Holdings, Inc. has a fifty-two week low of $54.69 and a fifty-two week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.